Top Markets
Coin of the day
Novan, Inc. Novan, Inc.

Novan, Inc.

NOVN
Rankning i aktier #39525
Novan, Inc. operates as a pre-commercial pharmaceutical entity specializing in... Novan, Inc. operates as a pre-commercial pharmaceutical entity specializing in nitric oxide-derived therapies for dermatological and anti-infective conditions. The company boasts a robust clinical-stage pipeline featuring several topical drug candidates. For skin-related ailments, these include SB204, a monotherapy aimed at acne vulgaris; SB206, an antiviral gel targeting viral skin infections; SB208, a broad-spectrum antifungal gel designed to combat various fungal skin and nail infections like athlete's foot; and SB414, a cream-based gel formulated for inflammatory skin diseases. Additionally, Novan is advancing SB207 to treat external genital warts, WH602 (an intravaginal gel) and WH504 (a non-gel formulation) both addressing high-risk human papillomavirus (HPV), and SB019, a candidate for SARS-CoV-2. The firm has cultivated strategic partnerships, holding a licensing agreement with Sato Pharmaceutical Co., Ltd., and engaging in a strategic alliance with Orion Corporation. Founded in 2006, Novan, Inc. maintains its headquarters in Durham, North Carolina.
Aktiekurs
$0.056
Senast synkroniserad: 2023-08-21
Marknadsvärde
$451.38K
Förändring (1 dag)
8.74%
Förändring (1 år)
0.00%
Land
US
Handel Novan, Inc. (NOVN)

Kategori

Utdelningsavkastning för Novan, Inc. (NOVN)
Utdelningsavkastningen (TTM) för Novan, Inc. (aktiesymbol: NOVN) per 2026 är: 0
Genomsnittlig utdelningsavkastning de senaste 5 åren: 0.00%
Historik för utdelningsavkastning för Novan, Inc. (NOVN) från 2026 till 2026
Utdelningsavkastning i slutet av varje år (TTM)
År Utdelningsavkastning Ändra
Inte tillräckligt med data för de angivna datumen.
Utdelningsavkastning (TTM) för liknande företag eller konkurrenter